Reslizumab as add-on therapy in patients with severe refractory asthma

This post-hoc analysis provides the first evidence that reslizumab may be beneficial for patients with severe refractory asthma and eosinophilia.
This post-hoc analysis provides the first evidence that reslizumab may be beneficial for patients with severe refractory asthma and eosinophilia.